European Commission Grants Conditional Marketing Authorization for Taiho’s LYTGOBI® Tablets for the Treatment of Adults With Cholangiocarcinoma
(Adnkronos) – LYTGOBI is the first irreversibly binding FGFR inhibitor in the European Union for use in the treatment of patients with cholangiocarcinoma ZUG, Switzerland, July 4, 2023 /PRNewswire/ — Taiho Oncology
